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Carotid artery stenting has emerged as an alternative to carotid endarterectomy for the treatment of severe extracranial carotid
stenosis in patients with anatomic or clinical factors that increase their risk of complications with surgery, yet there remains a
substantial amount of variability and uncertainty in clinical practice in the referral of patients for stenting vs endarterectomy.
By undertaking a thorough review of the literature, we sought to better define which subsets of patients with “high-risk”
features would be likely to preferentially benefit from carotid stenting or carotid endarterectomy. Although only a single
randomized trial comparing the outcomes of carotid stenting with distal protection and endarterectomy has been completed,
a wealth of observational data was reviewed. Relative to endarterectomy, the results of carotid stenting seem favorable in the
setting of several anatomic conditions that render surgery technically difficult, such as restenosis after prior endarterectomy,
prior radical neck surgery, and previous radiation therapy involving the neck. The results of stenting are also favorable among
patients with severe concomitant cardiac disease. Carotid endarterectomy, alternatively, seems to represent the procedure of
choice among patients 80 years of age or older in the absence of other high-risk features. Overall, existing data support the
concept that carotid stenting and endarterectomy represent complementary rather than competingmodes of therapy. Pending
the availability of randomized trial data to help guide procedural selection, which is likely many years away, an objective
understanding of existing data is valuable to help select the optimal mode of revascularization therapy for patients with severe
carotid artery disease who are at heightened surgical risk. (J Vasc Surg 2006;44:661-72.)Carotid endarterectomy (CEA), practiced since the
1950s, is an effective and durable method for treating severe
carotid bifurcation atherosclerotic disease. Over the past de-
cade, carotid artery stenting (CAS) has emerged as an alterna-
tive technique to treat extracranial carotid stenosis and has
raised the possibility of a dramatic paradigm shift in therapy.
As data have begun to emerge suggesting that CAS may be the
preferred therapy for certain patients at high risk for compli-
cations after CEA, controversy has shifted from a question of
whether carotid stenting is a clinically useful procedure to one
of when it is preferable to CEA. Much of the ongoing debate
regarding these two treatment modalities centers on precisely
which clinical factors predict increased surgical risk and to
what degree. The goal of this review was to evaluate the
concept of risk in relation to both CEA and CAS in an attempt
to help guide present-day clinical decision making and to
highlight gaps in knowledge that may serve as areas of further
investigation.
ENDARTERECTOMY AND STENTING:
PROSPECTIVE DATA
Several landmark randomized trials completed in the early
to mid 1990s established the superiority of CEA over medical
management for the treatment of several subgroups of pa-
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doi:10.1016/j.jvs.2006.05.042tients with extracranial carotid artery stenosis.1-5 In the North
American Symptomatic Carotid Endarterectomy Trial, CEA
among symptomatic patients with a 70% or greater stenosis
was associated with a nearly threefold relative reduction in the
incidence of stroke at 2 years compared with medical therapy
(26 vs 9%; P  .001).5 The incidence of perioperative adverse
cardiovascular events among patients treated with CEA was
5.8%, with major stroke occurring in 2.1% undergoing CEA.
In the Asymptomatic Carotid Endarterectomy Study, 1661
patients with an asymptomatic 60% or greater stenosis were
randomized to CEA or medical therapy.4 Surgical treatment
was associated with a 2.3% incidence of perioperative stroke or
death, and this was ultimately counterbalanced by a 53%
relative reduction in stroke or death at 5 years in the CEA arm
(5.1 vs 11.0%; P .004). In these trials, CEA was performed
by experienced surgeons, and patients with various comorbid
conditions associated with increased surgical risk were ex-
cluded (Table I). On the basis of a synthesis of data from all
available randomized controlled trials of CEA vs medical
therapy for symptomatic or asymptomatic carotid stenosis, the
American Heart Association has developed guidelines outlin-
ing the indications for CEA, which are based primarily on an
individual patient’s perceived surgical risk.6
In light of strong data supporting the clinical utility of
CEA, the emergence of CAS as a potential alternative
treatment for carotid disease over the past decade has sparked
considerable debate (Table II).7-10 CEA was initially pro-
posed as a treatment alternative for individuals with higher-
risk comorbidities that may have made them ineligible for
inclusion in the randomized trials of CEA vs medical therapy.
With the performance of observational11-15 and, subse-
quently, well-designed prospective trials and registries,16-21many of the initial theoretical arguments extolling the
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given way to data-based observations.
In the randomized prospective SAPPHIRE trial, 334
patients with an asymptomatic 80% or greater stenosis or a
symptomatic 50% or greater stenosis and 1 or more pre-
defined high-risk features (Table I) were assigned to CAS
with distal protection or CEA.21 At 30 days, the composite
Table I. ACAS and NASCET study exclusion criteria and
Category NASCET/ACAS exclusio
Anatomic Prior ipsilateral CEA
Radiation therapy to neck
Medical Age 80 y
Contralateral CEA within 4 mo
Significant cardiac disease
Unstable angina
MI within 6 mo of visit
Symptomatic CHF
Significant valve disease
Lung, liver, or renal failure
Uncontrolled hypertension or d
Protocol Tandem lesion  bifurcation
Stenosis 30% or 100%
Unable to consent
Other lesion that could cause sy
Previous stroke with profound d
Contralateral symptoms within
Nonhemispheric symptoms
Major surgery within 1 mo
Atrial fibrillation
Cancer with 50% 5-y survival
Allergic to aspirin or active ulce
Warfarin use
ACAS, Asymptomatic Carotid Atherosclerosis Study; NASCET, North Ame
RLN, recurrent laryngeal nerve; MI, myocardial infarction; CHF, congestiv
*“High-risk” factors defined by variables that would have excluded patient
Table II. Possible benefits of carotid endarterectomy and
carotid stenting
Carotid endarterectomy Carotid artery stenting
Proven short- and long-term
benefits compared with
medical therapy
Long-term outcomes well
characterized
Atherosclerotic plaque is
removed from artery (not
“displaced,” as with CAS)
No retained intravascular
foreign body
Permits avoidance of risks
associated with diagnostic
carotid angiography
Less invasive
Potentially safer in “sicker”
patients
Quicker recovery
Lower risk of wound-related
complications
Lower incidence of cranial
nerve injury
Ability to treat entire length of
the carotid artery
Safety not impaired by “hostile
neck” (prior neck surgery
or radiation)
Permits rapid visualization of
cerebral vessels and
neurologic rescue should
distal embolization occur
CAS, Carotid artery stenting.end point of stroke, large or small myocardial infarction(MI), or death occurred in 4.8% of patients randomized to
CAS and in 9.8% in the CEA group (P  .09). The 1-year
cumulative stroke and death rate remained 40% lower in
CAS patients (12.0% vs 20.1%; P .047), a difference that
persisted at 3 years.20,21 The need for repeat carotid revas-
cularization due to restenosis at 1 year was also significantly
lower among patients randomized to CAS (0.7% vs 4.6%;
P  .04). It should be stressed that SAPPHIRE was a
“noninferiority” study that was statistically powered to
demonstrate equivalency rather than superiority of CAS to
CEA among higher-risk patients.
Several industry-sponsored prospective multicenter
registries of CAS with embolic protection among patients
with high-risk features have yielded results similar to SAP-
PHIRE, with 30-day composite stroke/death/MI rates
ranging from 3.8% to 7.8% (Fig 1).16-19 Although these
studies have provided proof of concept for CAS among
individuals at increased risk for CEA, many knowledge gaps
persist.
THE CONCEPT OF RISK
Until the results of ongoing trials22 comparing CAS with
CEA among “lower-risk” individuals are known, CEA re-
mains the standard of care for treating patients with severe
carotid disease in the absence of concomitant medical or
anatomic conditions known to increase the risk of surgery.
Conversely, whereas CAS has often been touted as the proce-
dure of choice for patients requiring carotid revascularization
PHIRE inclusion criteria*
SAPPHIRE inclusion
Prior ipsilateral CEA
Radiation therapy to neck
Previous radical neck surgery
Contralateral RLN paralysis
Age 80 y
Contralateral carotid occlusion
Clinically significant cardiac disease
CHF
Abnormal stress test
Need for heart surgery within 30 d
Severe pulmonary disease
es
Stenosis severity
Symptomatic 50% stenosis or
Asymptomatic 80% stenosis
ms Either surgery or stenting feasible
Symptomatic Carotid Endarterectomy Trial; CEA, carotid endarterectomy;
t failure.
NASCET and/or ACAS or included patients in SAPPHIRE.SAP
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Although the likelihood of complications during CEA does
generally increase with increasing degrees of baseline patient
risk, some have erroneously concluded that the outcomes of
CAS are mostly independent of patient risk because of the less
invasive nature of CAS. In reality, comorbid conditions gen-
erally influence the relative safety of both CEA and CAS, but
often to differing degrees. As we will review, understanding
how various risk factors differentially affect the outcomes of
CEA and CEA forms the crux of the patient-selection process
for CEA vs CAS.
In clinical practice, we continue to observe a tremen-
dous amount of physician-to-physician variability related to
the referral of higher-risk patients for CEA vs CAS, and
decisions often seem to be influenced by physician subspe-
cialty, subjective biases, and incomplete knowledge of ex-
isting data, which to date have not been well summarized.
Our intention is to provide a literature-based, clinically
useful review outlining how various comorbidities influ-
ence outcomes after CAS and CEA.
INDIVIDUAL RISK FACTORS: METHOD
OF REVIEW
In an attempt to reduce potential bias in our review of the
literature, we considered all clinical studies of carotid stenting
and CEA in the setting of comorbid conditions encountered
by search of MEDLINE (1966 to March 2006), the Co-
Fig 1. Results of major “high-risk” carotid artery stenting (CAS)
prospective multicenter trials and registries. CAS in all trials was
performed with distal protection. CEA, Carotid endarterectomy;
MI, myocardial infarction; SAPPHIRE, Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterectomy trial;
ARCHeR, ACCULINK for Revascularization of Carotids in High
Risk Patients; SECURITY, Study to Evaluate the Neuroshield
Bare Wire Cerebral Protection System and X-Act Stent in Patients
at High Risk for Carotid Endarterectomy; BEACH, Boston Scien-
tific EPI-A Carotid Stenting Trial for High Risk Surgical Patients;
CABERNET, Carotid Artery Revascularization Using the Boston
Scientific FilterWire and the EndoTex NexStent; MAVeRIC, Eval-
uation of the Medtronic AVE Self-Expanding Carotid Stent Sys-
tem With Distal Protection In the Treatment of Carotid Stenosis.chrane Library Electronic Databases (2006), and abstractsfrom major scientific meetings (2003 to March 2006). Studies
that we found to be most relevant are those cited in this article
(Table III). The vast majority of studies were retrospective and
often reflected single-center experiences. Because of substan-
tial variations in patient populations treated in the different
studies, as well as dissimilarities in definitions and reporting of
adverse events and other key variables (Table IV), perfor-
mance of a systematic meta-analysis combining the results of
all studies of CEA and CAS was not feasible, although we
believe that the wealth of data available from these studies
provides a valuable and clinically useful basis for comparing
the relative safety CEA and CAS in the setting of various
high-risk features.
After our discussion of each risk factor, we provide a
brief objective summary of the published results of CEA
and CAS and then formulate an opinion based on our
review of the literature as to which form of revascularization
seems most favorable in that particular setting.
ANATOMIC RISK FACTORS
Recurrent stenosis after CEA
Carotid endarterectomy.23-35 Depending on defini-
tion, recurrent stenosis of any degree may occur in up to 50%
of cases after initially successful CEA, although the need for
reoperation is typically approximately 4%.36 Because resteno-
sis results from intimal hyperplasia without well-demarcated
tissue planes between the stenotic tissue and the vessel wall,
repeat CEA can pose technical challenges. Traditionally, re-
peat CEA has been associated with a higher incidence of
adverse clinical events than primary CEA, with operative
stroke and death rates exceeding 5% in several series (Table V).
The incidence of complications does seem to have improved
in more recent studies, possibly as a result of newer operative
techniques.26,35 Despite these apparent improvements in ma-
jor adverse event rates, cranial nerve injury remains a concern
among individuals undergoing redo CEA. In one series in
which 89 patients underwent comprehensive cranial nerve
examinations (including direct laryngoscopy) before and after
CEA for recurrent stenosis, a 21% incidence of cranial or
cervical nerve injury was noted.23
Carotid artery stenting.37-42 The fibrointimal nature
of recurrent stenoses may render these lesions less prone to
distal embolization during stenting compared with primary
atheromatous lesions, perhaps making CAS particularly valu-
Table III. Observational Studies of Carotid
Endarterectomy and Stenting Focusing on Particular
Comorbidities.
Comorbidity CEA CAS
Restenosis 23-35 37-42
Cervical Radiation 43-45 46, 47
High Bifurcation 48-52 56
Advanced Age 63-83 11, 85-88
Contralateral Occlusion 67, 91-95 95
Cardiac Disease 97-105 13, 107, 108able in this setting.37,38,40,41 Investigators at the Cleveland
l infar
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259 de novo lesions treated with CAS and found a trend
toward improved 30-day stroke/death rates in the restenotic
group (1.2% vs 3.1%).39 Among 338 patients with recurrent
Table V. Incidence of operative stroke or death
complicating redo carotid endarterectomy for recurrent
stenosis: retrospective studies
Author n
Operative
stroke or
death (%) Comments
Das28 65 4.6 9.2% incidence of cranial nerve
injury
Piepgras33 57 10.5 Fourfold increase in stroke or
death compared with first-
time CEA
Bartlett25 99 4.3 23% incidence of cranial nerve
injury
Meyer31 82 8.5
Coyle27 69 4.3 8.7% incidence of cervical
hematoma necessitating
drainage
Ballinger134 67 2.8
AbuRahma24 46 7.0
Mansour30 82 4.8 7.3% incidence of cranial nerve
injury
Rockman34 82 3.7 1.2% incidence of cranial nerve
injury
AbuRahma23 89 5.6 21% incidence of cranial nerve
injury
O’Hara32 206 3.9
Domenig29 86 2.3 Redo CEA not an
independent predictor of
operative stroke
Cho26 64 3.1
Stoner35 153 1.9 4.5% incidence of cranial nerve
injury
Table IV. Potential shortcomings of retrospective studies
Shortcoming
Absence of routine preprocedure/postprocedure
examinations by independent neurologist
Absence of routine cardiac enzyme determinations before
and after procedure
Differences in case mix, operative technique, and
definitions of adverse events between studies
Most reports originate from high-volume academic centers
The techniques and equipment used for CEA and CAS are
constantly evolving, especially for CAS with the use of
embolic protection over the past few years
Most retrospective studies of CEA focus on stroke and
death rates, and other potentially meaningful end points
may not be collected
Changing procedural costs and hospital length of stay with
CEA and CAS
CEA, Carotid endarterectomy; CAS, carotid artery stenting; MI, myocardiaCEA, Carotid endarterectomy.stenosis who underwent CAS as part of a 14-center registry,
the 30-day stroke/death rate was favorable, at 3.7%, with a
3-year freedom rate from fatal or nonfatal stroke of 96%.40
SUMMARY
1. Recent data demonstrate improving results with CEA
for recurrent stenosis; however, redo surgery is associ-
ated with a heightened risk of cranial nerve injury.
2. Data from two registries demonstrate favorable results
for CAS in the setting of recurrent stenosis.
Opinion. CAS seems to represent a reasonable alter-
native therapy to CAS, although the relative benefit of CAS
over CEA is probably modest.
Previous cervical radiation
Carotid endarterectomy.43-45 CEA traditionally has
been approached with caution among individuals who have
previously undergone neck irradiation for treatment of ma-
lignancy. Reasons for concern include absent tissue planes,
perivascular fibrosis, radiation arteritis, poor tissue healing,
and an increased likelihood of longer lesions with disease
extension beyond the usual limits for CEA.43 In a multivar-
iate analysis of 776 CEA procedures, Mozes et al45 found
prior cervical radiation to represent a highly significant
predictor of perioperative stroke (odds ratio, 15.2). In
another study, cranial nerve injury was observed in 25% of
postradiation cases.44
Carotid artery stenting.46-47 Although limited pub-
lished data exist, Harrod-Kim et al46 reviewed the results of
CAS performed on 23 vessels in patients with previous
radiation therapy for head and/or neck malignancy. There
was one procedural stroke and were no deaths, and three
vessels developed restenosis necessitating repeat percutane-
ous revascularization over a mean follow-up period of 28
rotid endarterectomy and carotid stenting
Potential result of shortcoming
erestimation of the true incidence of procedurally related
okes121,122
erestimation of procedural MI, a correlate of late mortality123,124
ct comparison of absolute complication rates between studies is
ficult
erestimation of the real-world incidence of complications, given
e relationship between procedural volumes and outcomes125-127
results of CAS studies from even a few years ago may not
urately reflect current practice, because CAS complication rates
ve decreased by up to 50% with distal protection128,129
r adverse events (eg, cranial nerve palsies and wound
mplications), a special concern in some high-risk subgroups, may
t be reported91,130
omic issues require better understanding131-133
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1. The irradiated neck poses a substantial technical chal-
lenge for CEA, with a heightened risk of cranial nerve
palsies and wound-related complications.
2. Limited published data exist for CAS in the setting of
prior neck irradiation, but the procedure is technically
feasible in this setting.
Opinion. Although it is uncertain whether CAS is
associated with lower rates of procedural stroke or death
than CEA after neck irradiation, CAS seems to represent a
reasonable alternative to CEA given its ability to essentially
negate the possibility of cranial nerve or wound-related
complications, a particular concern in this patient subset.
Because irradiation alters the biology of vascular cells and
may affect the healing process differently after surgical or
endovascular treatment, more data regarding the long-
term results after CAS are needed.
High bifurcation and distal plaque
Carotid endarterectomy.48-52 Plaque located in a
relatively distal location within the internal carotid artery,
whether resulting from a high carotid bifurcation or an
unusual degree of plaque extension up the vessel, also
represents a challenge to the surgeon. Although the defini-
tion of a “high” stenosis can vary, traditionally lesions
extending superior to a line drawn between the angle of the
mandible and the tip of the mastoid process (typically at the
level of the second cervical vertebral body) are included,53
and these are encountered in 1% to 6.7% of CEA proce-
dures.49-51 Because of limited surgical exposure, mandibu-
lar subluxation is at times necessary to provide a sufficient
operative field in which to perform CEA. Surgery may be
associated with an increased risk of cranial nerve injury,48,52
and an unusually high carotid bifurcation decreases the
chance that cervical block anesthesia will be successful,
thereby increasing the need for general anesthesia, which
may itself increase risk.54,55
Carotid artery stenting.56 Because CAS uses an intra-
vascular route of access, the ability to approach a stenosis with
a stent is typically not impaired if the stenosis extends to or
beyond the level of the C3 vertebra. Although published data
again are limited, Terada et al56 performed balloon angio-
plasty and/or stent placement in 24 patients with a symptom-
atic greater than 60% stenosis involving the petrous or cavern-
ous portion of the internal carotid artery and experienced only
1 adverse procedurally related neurologic event.
SUMMARY
1. The performance of CEA can be technical difficult in the
setting of high cervical carotid stenoses.
2. The performance of CAS is typically not affected if an
extracranial carotid stenosis extends beyond the C2
vertebral level.
Opinion. CAS seems to be the best option in this
setting.Aortic arch and carotid pathology
Carotid endarterectomy. Just as anatomic conditions
involving tissues of the neck external to the carotid artery, such
as scar tissue from prior neck surgery or radiation, typically
have negligible influence on the performance of CAS, intra-
vascular factors outside the range of the CEA operative field
may render CAS difficult without affecting the safety of CEA.
For example, extreme angulation of the great vessel origins
from the aorta may prohibit the passage of catheters and stents
to the target carotid artery, but this generally has no bearing
on the technical aspects of CEA. Similarly, extreme tortuosity
of the common or internal carotid artery may preclude safe
deployment of a stent or embolic protection device without
affecting the feasibility or safety of CEA. Conversely, severe
stenoses involving the ostium or proximal portion of the
common carotid artery or the innominate artery, for which
surgical exposure is quite involved, are typically more accessi-
ble for stenting by an endovascular approach.
Carotid artery stenting. Anatomic findings that rep-
resent relative contraindications to CAS include severe
atherosclerosis and/or calcification of the aortic arch, ex-
treme angulation of the great vessel origins from the aorta
(the so-called type 3 arch), severe tortuosity of the common
or internal carotid artery, and severe calcification of the
target carotid stenosis (Fig 2).57,58 Although anecdotal
descriptions of using a brachial artery approach exist, the
inability to obtain femoral artery access as a result of severe
peripheral vascular disease traditionally eliminates any at-
tempt at CAS. The presence of angiographically visible
thrombus in the carotid artery is considered an absolute
contraindication for CAS and is likewise associated an with
Fig 2. Illustration depicting anatomic problems that may increase
risk with carotid artery stenting. Some of these factors, such as a
calcified, angulated arch or difficult carotid anatomy, are proposed
mechanisms for the increased risk seen with advancing age.increased risk for adverse events during CEA.33
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frequency with which atheroemboli occur during CAS, 53
consecutive patients underwent diffusion-weighted image
magnetic resonance scanning before and after carotid stent-
ing. New cerebral defects were found in 40% of patients
(mean of 5.9 lesions per patient) after CAS, and, remark-
ably, 62% of these lesions occurred in territories not directly
supplied by the target carotid lesion. This suggests that
these emboli originated from the aorta, likely as a conse-
quence of catheter manipulation, rather than as a result of
stent placement in the target carotid artery.59
SUMMARY
1. The results of CEA are often unaffected by the presence
of several intravascular anatomic features that increase
the risk and complexity of CAS.
2. Subclinical cerebral embolic events seem to occur with
surprising frequency during CAS.
Opinion. Operator experience and judgment are cru-
cial to accurately estimate the degree to which any unfavor-
able anatomic feature will affect the risk of procedural
complications during CAS. For any CAS operator, the
ability to recognize and take heed of adverse anatomic
situations that favor abandoning attempts at stenting is
crucial. Even in a patient with a comorbid condition that
increases the risk for CEA, surgical (or perhaps medical)
therapy may still be preferable to CAS if significant ana-
tomic constraints are present that heighten the risk of CAS.
Other anatomic conditions
Carotid endarterectomy. The presence of a tracheos-
tomy stoma, which significantly compromises the sterile field
and renders cervical block anesthesia difficult because of po-
tential airway compromise, increases the risk of CEA.60 Neck
immobility resulting from cervical disk disease represents an-
other difficult subset of patients for CEA, because exposure of
the bifurcation is difficult and cervical block anesthesia is often
not feasible. Contralateral recurrent laryngeal nerve dysfunc-
tion has also been cited as a risk factor for CEA, because
unanticipated injury to the ipsilateral laryngeal nerve during
CEA may produce airway compromise.61,62
Carotid artery stenting. As previously discussed, be-
cause these anatomic issues are extravascular, CAS can
typically be performed without added difficulty.
Opinion. In general, external anatomic factors such as
the presence of a tracheostomy stoma, neck immobility,
and contralateral recurrent laryngeal nerve palsy increase
the technical complexity of CEA but not that of CAS, thus
favoring CAS.
MEDICAL RISK FACTORS
Advanced age
Carotid endarterectomy.63-83 Advanced age cur-
rently represents one of the most common, yet often inap-
propriate, indications for CAS in clinical practice. Because
the randomized trials of CEA excluded patients older than80 years, insights regarding the safety and efficacy of CEA
among individuals of advanced age come exclusively from
observational data. Many (but not all) studies indicate
modest trends toward increased procedural complications
as age increases (Table VI). For example, among 2089
Medicare beneficiaries who underwent CEA, 30-day mor-
tality increased with age, increasing from 1.1%, 2.8%, 3.2%,
and 4.7%, respectively, in those aged 65 to 69, 70 to 74, 75
to 80, and 80 years and older.84 At the University of
Rochester, although not statistically significant, trends fa-
vored a higher incidence stroke and death after CEA among
octogenarians (3.4%; n  148) compared with patients
younger than age 80 (1.8%; n  711).67
Carotid artery stenting.11,85-88 Advanced age repre-
sents a powerful correlate of procedural stroke and death
among patients undergoing CAS, whether or not cerebral
protection is used. In a retrospective analysis of 182 patients
who underwent unprotected CAS between 1994 and 1996,
the rate of neurologic complications (consisting primarily of
minor strokes) increased from 8.6% among patients younger
than 75 years to 25% among patients aged 80 years or more.85
Similarly, among 528 patients treated by Roubin and col-
leagues11 from 1994 to 1999, the composite 30-day inci-
dence of stroke and death increased from 6% among patients
less than 80 years old to 16% among those aged 80 and older.
Although one study failed to detect increased complication
rates among elderly CAS patients,87 Stanziale et al88 reported
a nearly threefold increase in procedural stroke, MI, or death
(9.2% vs 3.4%; P .02) after CAS among octogenarians in a
cohort of 386 patients. Likewise, interim analysis of the initial
749 patients who underwent CAS placement as part of the
lead-in registry for the ongoing Carotid Revascularization
Table VI. Thirty-day events after carotid endarterectomy
in the elderly: retrospective studies
Author n Stroke (%) Death (%)
Plecha76 782 2.2 2.3
Ouriel73 77 3.9 0
Rosenthal78 90 6.0 2.2
Schultz80 90 1.1 2.2
Pinkerton75 125 0 0.9
Meyer70 56 5.4 0
Treiman82 183 1.6 1.6
Coyle64 79 0 1.3
Favre65 52 5.8 1.9
Perler74 63 4.8 0
Van Damme83 129 0.8 2.3
Kerdiles68 281 1.1 1.4
Hoballah66 41 2.4 0
O’Hara71 182 2.7 0.6
Ballotta63 96 0 0
Maxwell69 218 3.2 2.9
Schneider79 90 1.1 0
Ting81 59 5.1 5.1
Ommer72 70 1.4 2.9
Rockman77 161 1.9 0
Illig67 148 3.0 1.0
Total 3072 2.2 1.5Endarterectomy vs Stent Trial (CREST) demonstrated a strik-
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plications (Fig 3).86
The etiology of neurologic events among elderly patients
undergoing CAS is unclear but seems related to increases in
both ischemic and hemorrhagic stroke, which can occur de-
spite the use of embolic protection. It has been noted that
aortic arch tortuosity and calcification become more common
with advanced age, thus increasing the likelihood of carotid
atheroemboli from the aorta during catheter manipulation.86
The elderly also seem to be at higher risk for clinically signifi-
cant problems related to baroreceptor-mediated bradycardia
and hypotension, commonly seen with distention of the ca-
rotid bulb during stent deployment.89
SUMMARY
1. The risk of neurologic complications related to CEA
seems to increase to a modest degree with advancing
age.
2. Patients older than 80 years who undergo CAS with or
without distal protection demonstrate a substantially
increased risk of stroke compared with younger patients.
Opinion. On the basis of these observations, the pres-
ence of advanced age alone, in the absence of other comor-
bid conditions, should not constitute an indication to
perform CAS in lieu of CEA. In fact, although no direct
comparative trials of CAS vs CEA have been undertaken in
the elderly, current retrospective data suggest that CEA
may be preferable to CAS among octogenarians requiring
carotid revascularization. As a special word of caution,
because of limited life expectancy, the very elderly represent
a subgroup in which the risks and benefits of undertaking
any form of carotid revascularization need to be weighed
with care, especially if the patient is asymptomatic with a
low (2%-3%) annual risk of stroke with conservative non-
Fig 3. Relationship between age and 30-day stroke and death
rates among patients who underwent carotid stenting in the lead-in
phase of CREST.operative treatment.90Contralateral carotid occlusion
Carotid endarterectomy.67,91-95 Occlusion of the
carotid artery contralateral to the vessel being treated with
CEA has been associated with an increased risk of periop-
erative stroke and death in some, but not all, studies. In the
North American Symptomatic Carotid Endarterectomy
Trial, contralateral occlusion conferred an independent
2.2-fold increase in the risk of 30-day stroke or death (9.4%
vs 4.4%) among patients undergoing CEA.91 Another re-
view of 1370 CEA procedures reported an overall operative
stroke rate of 6.7% among patients with contralateral oc-
clusion vs 1.1% overall, and contralateral occlusion repre-
sented the only significant predictor of an increased opera-
tive stroke rate among all variables examined.93 In a series
of 857 patients treated with CEA at our institution, the
presence of a contralateral occlusion was associated with a
nonsignificant trend toward increased procedural stroke
and death rates (3.8% vs 2.0%).67 Although contralateral
occlusion has not emerged as a predictor of complications
in other retrospective reviews of CEA,92,94,96 many sur-
geons advocate a strategy of routine intraoperative shunt-
ing in this setting given the increased potential for wide-
spread cerebral ischemia during the time that the lone
patent carotid artery is cross-clamped.
Carotid artery stenting.95 The technique of CAS
allows for only brief (usually 1 minute) occlusion of the
target carotid artery and, therefore, in theory, may be well
suited for patients with contralateral carotid occlusion.
Among 471 patients who underwent CAS in one series,
131 (28%) of whom had a contralateral severe stenosis or
occlusion, no differences in adverse event rates were ob-
served that were related to the presence or absence of
contralateral disease.95
SUMMARY
1. There are conflicting data regarding the relationship
between contralateral stenosis and surgical risk.
2. One large retrospective analysis suggests that CAS is safe
in the setting of a contralateral occlusion.
Opinion. Because of theoretical concerns and some
studies that suggest an increased stroke risk with CEA when
a contralateral occlusion is present, CAS may be preferable
in this situation, although any benefit, if present, is likely
modest. More data are required to better resolve this issue.
Cardiac disease
Carotid endarterectomy.97-105 Because arterioscle-
rosis is a systemic disease process, coronary and carotid
artery disease frequently coexist. In one series of patients
referred for coronary artery bypass grafting (CABG), for
example, 22% were found to have a carotid stenosis of 50%
or greater on carotid duplex screening.99 In addition, both
carotid artery disease and nonischemic cardiac disorders
(including valvular heart disease and congestive heart fail-
ure) tend to be diseases of the elderly and, therefore, may
also occur simultaneously.
prote
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and CEA consistently has been associated with increased
likelihoods of perioperative stroke, death, and MI com-
pared with stand-alone CEA.97,98,106 Among patients who
underwent combined CABG and CEA at the Cleveland
Clinic over a 10-year period ending in 1998, the rate of
death, stroke, or MI was 8.5% and increased to 15.5%
among individuals with medical comorbidities such as heart
failure, severe pulmonary disease, or renal insufficiency.97 A
query of the Medicare databases in 10 states during 1995
revealed an even greater 17.7% incidence of stroke or death
related to combined CEA/CABG procedures.106
Carotid artery stenting.13,107,108 Carotid stenting
has been evaluated as an alternative to CEA when severe
cardiac disease is present.107 In one series of 172 patients
who underwent CAS, 158 (92%) had concomitant angio-
graphically proven coronary artery disease, with 72 (42%)
undergoing coronary angioplasty concurrent with CAS.13
Despite the high-risk nature of the group, the procedural
stroke rate with CAS was 2.6%, with no deaths or MIs at 30
days. Ziada et al108 performed a retrospective analysis of
167 patients who underwent either combined CEA and
open heart surgery or CAS followed by open heart surgery
at their institution from 1997 to 2002. Patients who un-
derwent CAS before open heart surgery had a nearly
fourfold lower incidence of stroke and MI compared
with patients treated with combined CEA and cardiac
surgery (5% vs 19%; P  .02).
Potential concerns regarding the strategy of perform-
ing carotid stenting before CABG will require further res-
olution in larger studies, including (1) whether there is a
risk of thrombosis of the newly placed carotid stent during
subsequent CABG and (2) how to best manage antiplatelet
therapy with clopidogrel, typically continued for 4 weeks
after stent implantation, at the time of subsequent bypass
surgery, because clopidogrel is associated with an increased
potential for bleeding events during CABG.109,110
SUMMARY
1. Either combined or staged CABG and CEA are associ-
ated with increased likelihoods of perioperative stroke,
death, and MI compared with stand-alone CEA.
2. The results of CAS among patients with concomitant
Table VII. Summary of our general recommendations for
CEA strongly
recommended CEA preferred
Age 80 y Inability to use EPD H
Difficult aortic arch or carotid anatomy R
Difficult vascular access N
S
C
CEA, Carotid endarterectomy; CAS, carotid artery stenting; EPD, embolicsevere coronary disease seem favorable.Opinion. On the basis of a small but growing body
of data, CAS seems to be a safe mode of carotid revascu-
larization before open heart surgery in patients with
severe concomitant cardiac and carotid artery disease.
Among patients with lesser degrees of cardiac disease,
including those with stable angina, mild to moderate
valvular heart disease, and mild left ventricular dysfunc-
tion, CEA can typically be performed safely. Because of
the often-complex nature of patients with coexisting
cardiac and cerebrovascular disease, we strongly recom-
mend a multidisciplinary approach (potentially including
the cardiac surgeon, vascular surgeon and/or endovas-
cular specialist, cardiologist, and neurologist) to help
determine an effective treatment strategy on a patient-
by-patient basis.
Other medical comorbidities
Carotid endarterectomy. Perioperative risk with
CEA can be increased by several noncardiac comorbid
illnesses, including severe pulmonary and renal disease.
Poor lung capacity may preclude the use of general anes-
thesia, although regional anesthesia (cervical block) may be
a safer alternative in this setting.35,54,55,111-113 The pres-
ence of renal insufficiency has been described as a risk factor
for patients undergoing both CEA and CAS.29,114-116 In
one report examining the outcomes of 1001 patients who
underwent CEA, renal insufficiency (defined as serum cre-
atinine 1.5 mg/dL) was associated with significantly
increased rates of procedural stroke and death (6.9% vs
1.2%), wound hematoma formation (12.5% vs 1.6%), and
the overall complication rate (36.1% vs 6.2%).114 Conflict-
ing results have been published regarding the influence of
diabetes and sex on CEA outcomes.35,67,117,118
Carotid artery stenting. In an analysis of 581 patients
who underwent CAS, 190 of whom had chronic renal
insufficiency (defined as a glomerular filtration rate of 60
mL/min), renal insufficiency emerged as a significant risk
factor for procedural adverse events and was the strongest
clinical predictor of death, stroke, or MI at 6 months, with
a hazard ratio of 2.97.119 No systematic study of the
relationship between severe pulmonary disease and CAS
versus CAS
CAS preferred
CAS strongly
recommended
arotid bifurcation Prior neck radiation
ent stenosis Prior radical neck surgery
mmobility Tracheostomy stoma
cant cardiac or pulmonary disease
lateral recurrent laryngeal nerve
unction
ction device.CEA
igh c
ecurr
eck i
ignifi
ontra
dysfoutcomes has been published to date.
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1. Renal insufficiency is associated with an increased likeli-
hood of adverse outcomes for both CAS and CEA.
2. The relative influence of other medical comorbidities,
such as diabetes and sex, on CEA and CAS outcomes is
incompletely understood.
Opinion. Until direct comparative data among CAS,
CEA, and medical therapy become available for patients with
significant renal or pulmonary dysfunction, the perceived rel-
ative risks and benefits of each potential treatment strategy
should be carefully considered on case-to-case basis.
A caveat
Finally, and perhaps most importantly, it should be em-
phasized that for many high-risk patients, a more crucial
decision than deciding how to perform revascularization is to
determine whether any form of revascularization is preferable
to medical therapy. Although randomized trials have demon-
strated improved outcomes among low-risk patients random-
ized to CEA rather than medical therapy, no prospective
study, to our knowledge, has examined the benefits of carotid
revascularization relative to medical therapy among high-risk
patients. Carotid revascularization in essence represents a
trade-off in which, to be effective, the risk of operative stroke
needs to be outweighed by a lessened cumulative risk of stroke
over the ensuing years.120 Both aspects of this risk/benefit
equation are typically adversely affected by the presence of
comorbid conditions, because the comorbidities increase op-
erative risk while simultaneously reducing life expectancy. For
example, among 1370 patients who underwent CEA at
Brigham and Women’s Hospital over a 10-year period,
those without risk factors for surgery had a 5-year survival
rate of 75%, whereas patients with 2 or more surgical
comorbidities had a median survival of only 18 months.93
Table VIII. Further questions to answer
Questions that will help us
most clinically
Questions that will increase our
basic knowledge
Results of CAS in low-risk
patients
Randomized comparisons
of CEA, CAS, and
medical therapy for
age 80 y
Reasons for age-related risk
Aortic arch pathology?
Carotid tortuosity?
Decreased hemodynamic
reserve?
CEA: safety of general
anesthesia vs cervical
block
Uniform definition of
“high bifurcation” as
it relates to CEA risk
Prior radiation therapy: differential
effects on tissue healing after
CAS and CEA
Biology of restenosis after CEA
and CAS
Causes and prevention of
periprocedural myocardial
infarction
Residual plaque behavior after
CAS
Mechanism of high complication
rates for CEA and CAS with
renal insufficiency
CEA, Carotid endarterectomy; CAS, carotid artery stenting.Because, for example, low-risk patients who underwentCEA in the Asymptomatic Carotid Endarterectomy Study
did not demonstrate a benefit from the procedure until 3
years after surgery, the risk/benefit ratio of performing
either CAS or CEA among individuals with high-risk co-
morbid conditions needs to be weighed carefully on a
patient-by-patient basis.4 The Transatlantic Asymptomatic
Carotid Intervention Trial, which will involve three-way
randomization of high- and low-risk individuals with a
greater than 70% asymptomatic carotid stenosis to (1) CEA
plus aggressive medical therapy vs (2) CAS plus medical
therapy vs (3) aggressive medical therapy alone, is currently
in the planning stages and should provide invaluable infor-
mation.
RECOMMENDATIONS AND CONCLUSIONS
Both CEA and CAS are valuable techniques for treating
carotid bifurcation stenosis. For the clinician who is con-
fronted with a patient in whom carotid revascularization is
indicated, an objective, thorough, and dispassionate under-
standing of the relative risks and benefits of both CAS and
CEA in various settings is essential to determine the optimal
therapy. Table VII represents a succinct summary of the
authors’ opinions regarding the preferred mode of treatment
in the setting of various “high-risk” comorbidities discussed
throughout this review. It is critical to emphasize that such a
table, although valuable in summarizing our findings, cannot
take into account many complexities encountered in clinical
practice, including the presence of multiple simultaneous co-
morbidities, factors such as operator experience, and the op-
tion of pursuing medical therapy when the risks of either CEA
or CAS are deemed excessive. Although treatment decisions
will continue to be refined with the emergence of further data
(Table VIII) and with improvements in equipment and pro-
cedural techniques, it is clear that CAS and CEA are best
viewed as complementary rather than competing modes of
therapy that, when taken together, broaden therapeutic op-
tions in the treatment of carotid artery disease.
The authors thank Rocco Ciocca, MD, for his review of
this manuscript.
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